Equities

China Medical System Holdings Ltd

China Medical System Holdings Ltd

Actions
  • Price (HKD)7.35
  • Today's Change-0.300 / -3.92%
  • Shares traded5.67m
  • 1 Year change-46.51%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year China Medical System Holdings Ltd's revenues fell -12.43% from 9.15bn to 8.01bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 3.26bn to 2.40bn, a -26.33% decrease.
Gross margin74.13%
Net profit margin19.56%
Operating margin21.20%
Return on assets7.51%
Return on equity8.72%
Return on investment8.53%
More ▼

Cash flow in CNYView more

In 2023, China Medical System Holdings Ltd did not generate a significant amount of cash. However, the company earned 2.50bn from its operations for a Cash Flow Margin of 31.23%. In addition the company used 442.28m on investing activities and also paid 2.13bn in financing cash flows.
Cash flow per share0.7082
Price/Cash flow per share10.78
Book value per share7.08
Tangible book value per share5.38
More ▼

Balance sheet in CNYView more

China Medical System Holdings Ltd appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio4.28
Quick ratio3.97
Total debt/total equity0.0717
Total debt/total capital0.0667
More ▼

Growth rates in CNY

SmartText is unavailable
Div yield(5 year avg)4.14%
Div growth rate (5 year)5.19%
Payout ratio (TTM)40.00%
EPS growth(5 years)5.64
EPS (TTM) vs
TTM 1 year ago
-58.73
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.